Pre-Conference Workshop Day

Tuesday, December 7

WORKSHOP A

Investigating the Functional Synergy Between PD-1 & TIGIT in Immune Diseases

9am - 12pm EST

Following the success of PD-1 therapies in treating cancer, exploration of additional checkpoint axes has continued, leading to growing excitement surround the TIGIT pathway. As TIGIT becomes more clinically validated within the oncology space, there is a growing area of interest utilizing TIGIT to treat immune diseases, such as autoimmunity and alloimmunity.

Join this session to discuss:

  • Understanding the relationship between the function of TIGIT on APC cells and different autoimmune disease such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, colitis and dermatomyositis
  • Investigating the mechanisms of action of TIGIT in autoimmune & alloimmune diseases through in vitro and in vivo studies
  • Utilizing TIGIT+ Tregs as a marker for autoimmune disease
  • Validating TIGIT as a potential therapeutic target by applying agonistic TIGIT antibodies and inhibiting autoimmune & alloimmune disease to treat pre-clinical models
  • Rationalizing strategies to translate pre-clinical studies to the clinic

Workshop Leader

MicrosoftTeams-image
Karina Yazdanbaksh

Nicole Joller
Assistant Professor
University of Zurich

 

 

 

Karina Yazdanbakhsh
Vice President and Director of Research Development
Lindsley F. Kimball Research Institute, New York Blood Centre

WORKSHOP B

Elucidating the Anti-Tumor Immunity of Other Immune Checkpoint Inhibitors & Combinations in Oncology

1pm - 4pm EST

Despite the triumphs in the immuno-oncology space over the past 10 years, the rate of FDA approval of immunotherapies is decreasing. As the checkpoint inhibitor landscape becomes more crowded, it is paramount that we define the unique features of checkpoint inhibitors and establish how they interplay to inform drug strategies which provide the best patient outcomes.

Join this session to discuss:

    • Making sense of the anti-tumor immunity of other checkpoint inhibitors such as PD-L1/1, CD39, LAG-3, CTLA-4, PVRIG to better understand their mechanism of action in clinical populations
    • Discussing how these pathways relate to each other to influence cell biology and promote cancer development
    • Outlining the clinical landscape, key players and key molecules of Immune Checkpoint Inhibitors and their potential to improve endpoints for patients
      Exploring key considerations when designing safe and efficacious checkpoint inhibitors
    • Supercharging immune checkpoint inhibitor therapies using kinase targeting and holistic immune cell approaches
    • Looking into the future of ICI: Modifying the main end-point of ICI clinical trials to accommodate delayed effect of ICIs and optimization of ICI regimes with biomarkers for efficacy and toxicity

Workshop Leader

Farahnaz Forozan
W-IEO-P-4752-Bald_Tobias-2021-07-13-009956-1
Pini Tsukerman

Farahnaz Forozan
President
OncoGen Forozan Consulting

 

Tobias Bald
Professor of Tumoimmunobiology
Univeristy Hospital Bonn

 

 

Pini Tsukermann
Chief Scientific Officer
Nectin Therapeutics